Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd
Your view on CU6.AX
Overview
What the company does, where it operates, and who runs it.
About Clarity Pharmaceuticals Ltd
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Michelle Parker
- Headquarters
- National Innovation Centre, Sydney, NSW, AU
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Michelle Parker
- Headquarters
- National Innovation Centre, Sydney, NSW, AU
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Clarity Pharmaceuticals Ltd, and the rating behind it. CU6.AX last traded at AUD 2.69; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Clarity Pharmaceuticals Ltd. Starting points for Clarity Pharmaceuticals Ltd: EPS -AUD 0.27, beta 1.18 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Clarity Pharmaceuticals Ltd. Clarity Pharmaceuticals Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Clarity Pharmaceuticals Ltd. Trailing twelve-month EPS for Clarity Pharmaceuticals Ltd stands at -AUD 0.27. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Clarity Pharmaceuticals Ltd. Clarity Pharmaceuticals Ltd has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Clarity Pharmaceuticals Ltd valued side by side against its closest peers. Clarity Pharmaceuticals Ltd is measured against Medical - Specialties peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Clarity Pharmaceuticals Ltd, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Clarity Pharmaceuticals Ltd executives and directors. Shares of Clarity Pharmaceuticals Ltd have traded between AUD 1.80 and AUD 5.87 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Clarity Pharmaceuticals Ltd. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Clarity Pharmaceuticals Ltd. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Clarity Pharmaceuticals Ltd. Coverage tracks Clarity Pharmaceuticals Ltd within Medical - Specialties (Healthcare). Press releases and market coverage, newest first.